Treating dementia by blood brain barrier opening to increase glymphatic clearance - From mechanisms to therapeutic applications

Description of the granted funding

Alzheimer's disease (AD) currently complicates the lives of 50 million people with deterioration of mental skills and personality. Today AD costs 1 trillion € annually and by 2030 the cost will double. In OPEN-consortium we have detected failures in a brain clearance mechanism that lead to AD. Based on our findings, we have further developed novel tools for detecting the failing brain clearance along with new ways to boost the brain clearance, such that the AD development might be slowed down or even prevented. In the continued plans are that we will further increase the efficiency of the treatment options and expand our research to see how efficient our tools are in detecting and monitoring AD pathology in humans. We aim to develop novel multi-level treatment strategy that incorporates a spectrum of options extending from easy to use non-invasive therapies into more invasive treatments for advanced diseases states that can be tailored to suite patient treatment at individual level.
Show more

Starting year

2021

End year

2023

Granted funding



Teemu Myllylä
162 500 €

Role in consortium of the Academy of Finland

Partner

Other consortium parties

Partner
University of Oulu (335722)
162 500 €
Leader
University of Oulu (335720)
162 500 €

Funder

Research Council of Finland

Funding instrument

Academy programme

Other information

Funding decision number

335723

Fields of science

Biochemistry, cell and molecular biology

Research fields

Solu- ja molekyylibiologia

Identified topics

brain, neuroscience